These findings position CLDN18.2-directed therapies (e.g., antibody-drug conjugates, CAR-T) as viable strategies for ICC, particularly when integrated with immune checkpoint inhibitors. Here, CLDN18 is linked to intrahepatic cholangiocarcinoma.